Multidrug-resistant gram-negative organisms: a review of recently approved antibiotics and novel pipeline agents

Coumarin: a novel player in microbial quorum sensing and biofilm formation inhibition

(2018) F. Jerry Reen et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation

(2018) Stephanie N Taylor et al.   CLINICAL INFECTIOUS DISEASES

Phenylthiazoles with tert -Butyl side chain: Metabolically stable with anti-biofilm activity

(2018) Ahmed Kotb et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Murepavadin: a new antibiotic class in the pipeline

(2018) Ignacio Martin-Loeches et al.   Expert Review of Anti-Infective Therapy

Antibiotic-Resistant Infection Treatment Costs Have Doubled Since 2002, Now Exceeding $2 Billion Annually

(2018) Kenneth E. Thorpe et al.   HEALTH AFFAIRS

Evaluating the anti -biofilm and antibacterial effects of Juglans regia L. extracts against clinical isolates of Pseudomonas aeruginosa

(2018) Samaneh Dolatabadi et al.   MICROBIAL PATHOGENESIS

Global increase and geographic convergence in antibiotic consumption between 2000 and 2015

(2018) Eili Y. Klein et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

(2017) Thomas F. Durand-Réville et al.   Nature Microbiology

In VitroActivity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens

(2016) D. J. Biedenbach et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A review of global initiatives to fight antibiotic resistance and recent antibiotics׳ discovery

(2016) Arpana Sagwal Chaudhary   Acta Pharmaceutica Sinica B

In VitroActivity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens

(2015) Douglas J. Biedenbach et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The global challenge of new classes of antibacterial agents: an industry perspective

(2015) Prabhavathi Fernandes   CURRENT OPINION IN PHARMACOLOGY

Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

(2015) Gregory S. Basarab et al.   Scientific Reports

RND-type drug efflux pumps from Gram-negative bacteria: molecular mechanism and inhibition

(2015) Henrietta Venter et al.   Frontiers in Microbiology

Combating multidrug-resistant Gram-negative bacterial infections

(2013) Ze-Qi Xu et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Antimicrobial resistance: action to combat the rising microbial challenges

(2013) Niki I. Paphitou   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Novel classes of antibiotics or more of the same?

(2011) Anthony RM Coates et al.   BRITISH JOURNAL OF PHARMACOLOGY

Combating Antimicrobial Resistance: Policy Recommendations to Save Lives

(2011)   CLINICAL INFECTIOUS DISEASES

Type IIA topoisomerase inhibition by a new class of antibacterial agents

(2010) Benjamin D. Bax et al.   NATURE

The global need for effective antibiotics: challenges and recent advances

(2010) Liselotte Diaz Högberg et al.   TRENDS IN PHARMACOLOGICAL SCIENCES